Our investments

Deinobiotics

Deinobiotics was founded in 2009 by Deinove, (Truffle Capital portfolio), with the support of OSEO-ERDF. Deinobiotics is a subsidiary dedicated to the research and development of antibiotics and antifungals. The current R&D program targets mainly antibiotics capable of fighting against resistant hospital germs responsible for nosocomial infections (gram-negative bacteria and fungi).

Antoine Pau is a member of the Board of Directors.

First FinTech Closing
On the 15th of November 2017, Truffle has successfully completed the first closing of its institutional fund Truffle Financial Innovation Fund.
Premier closing FinTech
Le 15/11/2017, Truffle réalise le premier closing de son fonds institutionnel Truffle Financial Innovation Fund.
Premier closing FinTech
Le 15/11/2017, Truffle réalise le premier closing de son fonds institutionnel Truffle Financial Innovation Fund.